Entrada Therapeutics has secured authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to ...
ENTR-601-44 is a proprietary Endosomal Escape Vehicle (EEV™)-conjugated phosphorodiamidate morpholino oligomer (PMO) designed to restore the mRNA reading frame and allow for the production of a ...
Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...
The Elevate-44-201 study is a global, two-part, randomized, double-blind placebo-controlled phase 1/2 study evaluating the ...
Jefferies projects a peak opportunity of at least $3 billion for DYNE-101. Dyne is also running another candidate—the phosphorodiamidate morpholino oligomer DYNE-251 being tested for Duchenne muscular ...
Microinjection of Eml1-MO and Eml1-3DDK mRNA Morpholino oligomers for EML1 (EML1-MO, 5′-TAG CTGGAGAAGCCGTCCTCCATGC-3′) and the Standard Control (Control-MO, 5′-CCTCTTACCTCAGTTACAATTT ATA-3′) were ...
at pH 7.0 with 0.165 M of 3-(N-morpholino) propanesulfonic acid (MOPS) and 0.4% of dimethyl sulfoxide (DMSO) as a solubilizing agent. 8 The standard powder used to prepare nystatin was dissolved in ...
Entrada Therapeutics plans to initiate ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy by Q2 2025. Entrada Therapeutics, Inc. announced that it has received regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback